Decreased expression of ten-eleven translocation 1 protein is associated with some clinicopathological features in gastric cancer

Biomedicine and Pharmacotherapy

Volumn 68, Issue 2, 2014, Pages 209-212

  Frycz, Bartosz Adam ^a   Murawa, Dawid ^b   Borejsza Wysocki, Maciej ^a   Marciniak, Ryszard ^a   Murawa, Paweł ^b   Drews, Michał ^a   Kołodziejczak, Anna ^a   Tomela, Katarzyna ^a   Jagodziński, Paweł Piotr ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Wielkopolska Cancer Center   (Poland)

Author keywords

5 Hydroxymethylcytosine (5hmC); Gastric cancer; TET1

Indexed keywords

PROTEIN; TEN ELEVEN TRANSLOCATION 1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TISSUE LEVEL; TUMOR INVASION; TUMOR LOCALIZATION; WESTERN BLOTTING;

5-HYDROXYMETHYLCYTOSINE (5HMC); GASTRIC CANCER; TET1;

AGE FACTORS; AGED; BLOTTING, WESTERN; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SEX CHARACTERISTICS; STOMACH; STOMACH NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84897059011     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.12.011     Document Type: Article

References (39)

1. Crew K.D., Neugut A.I. Epidemiology of gastric cancer. World J Gastroenterol 2006, 12(3):354-362.
2. Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012, 4:156-169.
3. Gigek C.O., Chen E.S., Calcagno D.Q., Wisnieski F., Burbano R.R., Smith M.A. Epigenetic mechanisms in gastric cancer. Epigenomics 2012, 4(3):279-294.
4. Calcagno D.Q., Gigek C.O., Chen E.S., Burbano R.R., Smith Mde A. DNA and histone methylation in gastric carcinogenesis. World J Gastroenterol 2013, 19(8):1182-1192.
5. Luczak M.W., Jagodziński P.P. The role of DNA methylation in cancer development. Folia Histochem Cytobiol 2006, 44(3):143-154.
6. Rountree M.R., Bachman K.E., Herman J.G., Baylin S.B. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001, 20(24):3156-3165.
7. Ooi S.K., Bestor T.H. The colorful history of active DNA demethylation. Cell 2008, 133(7):1145-1148.
8. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324(5929):930-935.
9. Delatte B., Fuks F. TET proteins: on the frenetic hunt for new cytosine modifications. Brief Funct Genomics 2013, 12(3):191-204.
10. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333(6047):1300-1303.
11. Szwagierczak A., Bultmann S., Schmidt C.S., Spada F., Leonhardt H. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res 2010, 38(19):e181.
12. Xu Y., Wu F., Tan L., Kong L., Xiong L., Deng J., et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 2011, 42(4):451-464.
13. Williams K., Christensen J., Pedersen M.T., Johansen J.V., Cloos P.A., Rappsilber J., et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011, 473(7347):343-348.
14. Jin S.G., Jiang Y., Qiu R., Rauch T.A., Wang Y., Schackert G., et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 2011, 71(24):7360-7365.
15. Kudo Y., Tateishi K., Yamamoto K., Yamamoto S., Asaoka Y., Ijichi H., et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci 2012, 103(4):670-676.
16. Yang H., Liu Y., Bai F., Zhang J.Y., Ma S.H., Liu J., et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013, 32(5):663-669.
17. Yang Q., Wu K., Ji M., Jin W., He N., Shi B., et al. Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol 2013, 9(9):1607-1616.
18. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 1987, 162:156-159.
19. Radonic A., Thulke S., Mackay I.M., Landt O., Siegert W., Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 2004, 313(4):856-862.
20. Ficz G., Branco M.R., Seisenberger S., Santos F., Krueger F., Hore T.A., et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011, 473(7347):398-402.
21. Wu H., D'Alessio A.C., Ito S., Xia K., Wang Z., Cui K., et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 2011, 473(7347):389-393.
22. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466(7310):1129-1133.
23. Koh K.P., Yabuuchi A., Rao S., Huang Y., Cunniff K., Nardone J., et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011, 8(2):200-213.
24. Ruzov A., Tsenkina Y., Serio A., Dudnakova T., Fletcher J., Bai Y., et al. Lineage-specific distribution of high levels of genomic 5-hydroxymethylcytosine in mammalian development. Cell Res 2011, 21(9):1332-1342.
25. Kinney S.R., Pradhan S. Ten eleven translocation enzymes and 5-hydroxymethylation in mammalian development and cancer. Adv Exp Med Biol 2013, 754:57-79.
26. Valinluck V., Sowers L.C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007, 67(3):946-950.
27. Iyer L.M., Tahiliani M., Rao A., Aravind L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 2009, 8(11):1698-1710.
28. Wu H., Zhang Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 2011, 25(23):2436-2452.
29. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145(3):423-434.
30. Zhang L., Lu X., Lu J., Liang H., Dai Q., Xu G.L., et al. Thymine DNA glycosylase specifically recognizes 5-carboxylcytosine-modified DNA. Nat Chem Biol 2012, 8(4):328-330.
31. Song C.X., He C. Balance of DNA methylation and demethylation in cancer development. Genome Biol 2012, 13(10):173.
32. Lian C.G., Xu Y., Ceol C., Wu F., Larson A., Dresser K., et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150(6):1135-1146.
33. Hsu C.H., Peng K.L., Kang M.L., Chen Y.R., Yang Y.C., Tsai C.H., et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep 2012, 2(3):568-579.
34. Liu C., Liu L., Chen X., Shen J., Shan J., Xu Y., et al. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One 2013, 8(5):e62828.
35. Müller T., Gessi M., Waha A., Isselstein L.J., Luxen D., Freihoff D., et al. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am J Pathol 2012, 181(2):675-683.
36. Huang H., Jiang X., Li Z., Li Y., Song C.X., He C., et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A 2013, 110(29):11994-11999.
37. Orr B.A., Haffner M.C., Nelson W.G., Yegnasubramanian S., Eberhart C.G. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One 2012, 7(7):e41036.
38. Gaidzik V.I., Paschka P., Späth D., Habdank M., Köhne C.H., Germing U., et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012, 30(12):1350-1357.
39. Tan L., Shi Y.G. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 2012, 139(11):1895-1902.